Osiris Therapeutics


Brean Capital Reiterates Upbeat View of Osiris Therapeutics Following 4Q Earnings

In a research report published Friday, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics, Inc. (NASDAQ:OSIR) with a $19.

Brean Capital Provides Key Takeaways From One On One With Osiris CEO

In a research report sent to investors today, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics (NASDAQ:OSIR) with a …

Zack’s Bull of the Day: Osiris Therpeutics

Osiris Therapeutics (NASDAQ:OSIR) stem cells aren’t the big source of buzz they were just a few years ago. We have moved on to …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts